Profits at Biogen Idec Inc. surged in the second quarter on strong sales of Tecfidera (dimethyl fumarate) and its other multiple sclerosis (MS) therapies, beating analyst expectations and pumping up sales forecasts as the company notched a new drug approval in Europe.